

EVANESCO - Cohort Event monitoring of COVID-19 vAcciNE Safety in France using patient-reported outCOmes

Head :Thurin Nicolas, Bordeaux PharmacoEpi (BPE) Research Platform - Inserm CIC1401

Last update : 03/07/2023 | Version : 2 | ID : 73996

General

Identification

Detailed name Cohort Event monitoring of COVID-19 vAcciNE Safety in France using patient-reported outCOmes

Sign or acronym EVANESCO

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation ID-RCB : 2020-A03554-35; CPP : 21.01.14.466.31

General Aspects

Medical area Infectious diseases

Study in connection with Covid-19 Yes

Pathology (details) Patient-reported adverse drug reactions following COVID-19 vaccination

Health determinants Iatrogenic Medicine

Keywords COVID-19, vaccines, adverse drug reactions

Scientific investigator(s) (Contact)

Name of the director Thurin

Surname Nicolas

Address Bordeaux PharmacoEpi - INSERM CIC1401
Université de Bordeaux
Bâtiment Le Tondu - Case 41
146, Rue Léo Saignat
33076 BORDEAUX Cedex

Unit Bordeaux PharmacoEpi (BPE) Research Platform - Inserm CIC1401

Organization University of Bordeaux

Collaborations

Participation in projects, networks and consortia Yes

Details European consortium coordinated by Utrecht University, Netherlands; Participant Centres: Pharmacovigilance Centre LAREB, Netherlands; Federal Agency for Medicines and Health Products, Belgium; Luxembourg Institute of Health, Luxembourg; University of Verona, Italy; University of Bordeaux, France; DSRU, England; Paul Ehrlich Institute, Germany; HALMED, Croatia

Funding

Funding status Public

Details EMA and the French Ministry of Health

Governance of the database

Sponsor(s) or organisation(s) responsible University of Bordeaux, Bordeaux PharmacoEpi (BPE) Research Platform Inserm CIC1401

Organisation status Both

Presence of scientific or steering committees No

Additional contact

Name of the contact Dureau-Pournin

Surname Caroline

Address Bordeaux PharmacoEpi - INSERM CIC1401
Université de Bordeaux
Bâtiment Le Tondu - Case 41
146, Rue Léo Saignat
33076 BORDEAUX Cedex

Email caroline.dureau@u-bordeaux.fr

Unit Bordeaux PharmacoEpi (BPE) Research Platform - Inserm CIC1401

Organization University of Bordeaux

Main features

Type of database

Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Recruitment of participants at vaccination centres and pharmacies with collection of primary data directly from individuals vaccinated against COVID-19 via a dedicated secure online application.

Database objective

Main objective	To generate incidence rates of patient-reported Adverse Drug Reaction (ADR) of brand specific COVID-19 vaccination in France, in near real time.
----------------	--------------------------------------------------------------------------------------------------------------------------------------------------

Inclusion criteria	<ul style="list-style-type: none">- To describe ADR incidence rates according to brand of vaccine and to specific populations such as, pregnant women, patients with severe co-morbidities (e.g., frail, vaccinees with auto-immune diseases), elderly, children, patients having recently received other vaccines;- To detect potential novel safety signals;- To identify possible risk factors for ADR.
--------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Population type

Age	Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
-----	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Population covered	General population
--------------------	--------------------

Pathology

Gender	Male Woman
--------	---------------

Geography area	National
Detail of the geography area	Vaccination centers at the national level and pharmacies in Bordeaux agreeing to provide information on the study to those vaccinated.
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2021
Date of last collection (YYYY or MM/YYYY)	2023
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	6,640 vaccinated individuals in France
Data	
Database activity	Current data collection
Type of data collected	Declarative data
Declarative data (detail)	Internet self-questionnaire
Details of collected declarative data	Date of birth, gender, weight, height, name of vaccine, batch number, vaccination date, place of vaccination, medical history including previous COVID-19 infection, pregnancy, occupation if related to health care, medication taken, adverse reactions occurring after vaccination (type, date, duration, medication taken, examinations performed, seriousness, outcome, impact on daily life), COVID-19 infection after vaccination
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health event/mortality Others
Other (detail)	Adverse drug reactions occurring after vaccination against COVID-19
Procedures	

Data collection method	Data collection via a dedicated secure online application, with data entry by the vaccinated individuals.
Classifications used	MedDRA coding of adverse reactions
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the participant (mail, e-mail, telephone etc.)
Details on monitoring of participants	Vaccinated individuals receiving one dose of vaccine, 1st dose or booster dose, followed for 3 to 6 months via self-administered questionnaires to be completed by internet at inclusion, 1, 2, 6, 8 weeks, then 3 and 6 months, if applicable, after the start of the vaccination
Links to administrative sources	Yes
Linked administrative sources (detail)	SNDS, SI-Vaccine COVID and SI-DEP with 2 years of history and 1 year of follow-up: probabilistic chaining
Promotion and access	
Promotion	
Access	